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Abstract
Introduction We have previously reported that tumour-specific
expression of the rate-limiting enzyme, 3-hydroxy-3-
methylglutharyl-coenzyme A reductase (HMG-CoAR), in the
mevalonate pathway is associated with more favourable tumour
parameters in breast cancer. In the present study, we examined
the prognostic value of HMG-CoAR expression in a large cohort
of primary breast cancer patients with long-term follow up.
Methods The expression of HMG-CoAR was assessed by
immunohistochemistry on tissue microarrays with tumour
specimens from 498 consecutive cases of breast cancer with a
median follow-up of 128 months. Kaplan Meier analysis and Cox
proportional hazards modelling were used to estimate the rate
of recurrence-free survival (RFS) and breast cancer specific
survival (BCSS).
Results In line with our previous findings, tumour-specific HMG-
CoAR expression was associated with low grade (p < 0.001),
small size (p = 0.007), oestrogen receptor (ER) positive (p =
0.01), low Ki-67 (p = 0.02) tumours. Patients with tumours
expressing HMG-CoAR had a significantly prolonged RFS, even
when adjusted for established prognostic factors (relative risk
[RR] = 0.60, 95% confidence interval [CI] 0.40 to 0.92; p =
0.02). In ER-negative tumours, however, there was a trend, that
was not significantly significant, towards a shorter RFS in HMG-
CoAR expressing tumours.
Conclusions HMG-CoAR expression is an independent
predictor of a prolonged RFS in primary breast cancer. This may,
however, not be true for ER-negative tumours. Further studies
are needed to shed light on the value of HMG-CoAR expression
as a surrogate marker of response to statin treatment, especially
with respect to hormone receptor status.
Introduction
The enzymatic activity of 3-hydroxy-3methylglutharyl-coen-
zyme A reductase (HMG-CoAR) is elevated in cancer cells [1].
HMG-CoAR acts as a rate-limiting enzyme in the mevalonate-
pathway, in which the main product is cholesterol. However,
the pathway also produces a number of non-sterol isoprenoid
side products, which have been shown to be important regu-
lators of several oncogenic properties including angiogenesis,
proliferation and migration [2,3]. Thus, increased levels of
tumour-specific HMG-CoAR might reflect an increased
demand of isoprenoids to maintain growth advantages within
the cancer cell [1].
HMG-CoAR inhibitors, also known as statins, commonly used
in the treatment of hypercholesterolaemia, have demonstrated
anti-neoplastic effects in vitro [4-6]. Both the isoprenoid-medi-
ated anti-tumoural effects and the cholesterol-lowering effects
of statins have been suggested to lower the incidence of can-
cer among statin users [7]. Epidemiological studies have not
been able to agree on an association between statin use and
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overall breast cancer risk [8,9]; however, a lower incidence of
oestrogen receptor (ER) negative tumours has been reported
among statin users [10]. Furthermore, an inverse relationship
between statin use after diagnosis and breast cancer recur-
rence has been reported [11].
In a recently published study [12], we investigated the tumour-
specific expression of HMG-CoAR by immunohistochemistry
in 511 cases of incident breast cancer within the population-
based prospective cohort of the Malmö Diet and Cancer
Study (MDCS) [13]. This study demonstrated that HMG-
CoAR was expressed at various intensities in 82% of the
tumours and increased levels of HMG-CoAR protein expres-
sion were associated with favourable tumour characteristics
such as a smaller tumour size, low histological grade and ER
positivity. However, due to a small number of breast-cancer
related events in the MDCS, it was not possible to perform
survival analyses in relation to expression of the tumour-spe-
cific, HMG-CoAR protein. In the present study we therefore
aimed to analyse HMG-CoAR protein expression by immuno-
histochemistry in a consecutive cohort of 498 patients with
invasive breast cancer with long-term follow-up. The aim of this
study was to examine the relationship between HMG-CoAR
expression and disease outcome as well as established clin-
icopathological parameters.
Materials and methods
Patients
This study included 498 patients with primary invasive breast
cancer treated and diagnosed at the Malmö University Hospi-
tal between 1 January 1988 and 31 December 1992. The
cases belonged to an original cohort of 512 patients [14]. The
median age at diagnosis was 65 years (range 27 to 96 years)
and median follow-up time to first breast cancer event was
128 months (range 0 to 207 months). Information regarding
the date of death was obtained from the regional cause-of-
death registries for all patients. Complete treatment data were
available for 379 (76%) patients, 160 of whom had received
adjuvant tamoxifen. Information on adjuvant systemic chemo-
therapy was available for 382 patients, of which only 23
patients had received treatment. Two hundred patients
received no adjuvant systemic treatment. Ethical permission
was obtained from the Local Ethics Committee at Lund Univer-
sity (Dnr 613/02), whereby informed consent was deemed not
to be required, but opting out was an option.
Tissue microarray construction
For the present study, new tissue microarrays (TMAs) were
constructed as described previously [15]. In brief, two 1.0 mm
cores were taken from areas representative of invasive cancer
and mounted in a recipient block using a manual arraying
device (MTA-1, Beecher Inc, WI, USA).
Immunohistochemistry
As described previously[16], sections 4 μm in diameter were
dried, deparaffinised, rehydrated and treated in a microwave
for two rounds of five minutes in citrate buffer before being
stained in a Techmate 500 (DAKO, Copenhagen, Denmark)
with a polyclonal anti-HMG-CoAR antibody (Catalog # 07-
457, Upstate) diluted 1:250.
For all other antibodies, heat-mediated antigen retrieval was
performed using microwave treatment for two rounds of five
minutes in a citrate buffer before being processed either in the
Ventana Benchmark system (Ventana Medical Systems Inc,
AZ) using pre-diluted antibodies to ER (Anti-ER, clone 6F11),
progesterone receptor (PR; Anti-PgR, clone 16) and human
epidermal growth factor receptor 2 (HER2; Pathway CB-USA,
760-2694) or in the Dako Techmate 500 system (Dako, Glos-
trup, Denmark) for Ki-67 (1:200, M7240; Dako, Glostrup,
Denmark).
Cytoplasmic staining of HMG-CoAR was assessed both as
the fraction of positive cells (0 to 1%, 2 to 10%, 11 to 50%
and 51 to 100%) and the staining intensity in the cytoplasm
(negative = 0, weak = 1, moderate = 2, strong = 3). ER, PR,
HER2 and Ki-67 were assessed as previously described [14].
ER and PR negativity was defined as less than 10% positively
staining nuclei, according to current clinical guidelines in
Sweden.
Statistical analysis
Differences in distribution of clinical data and tumour charac-
teristics between HMG-CoAR-negative and HMG-CoAR-pos-
itive tumours were evaluated using the chi-squared test. The
Kaplan-Meier analysis and the log rank test were used to illus-
trate differences between recurrence free survival (RFS) and
breast cancer-specific survival (BCSS) according to HMG-
CoAR expression. Cox regression proportional hazards mod-
els were used to estimate the impact of HMG-CoAR expres-
sion on RFS and BCSS in both univariate and multivariate
analysis, adjusted for tumour size, ER, HER2, lymph node sta-
tus and Nottingham histological grade (NHG) of the entire
cohort. Repeated analyses were performed on ER-positive
and ER-negative patients separately. The null hypothesis of
prognostic effects of HMG-CoAR status in ER-positive and
ER-negative patients were evaluated using a Cox model with
a term for the interaction between ER status and HMG-CoAR
status (ER status [+/-] X HMG-CoAR status [+/-]) also
included adjustment for established prognostic factors. All cal-
culations were performed using SPSS version 15.0 (SPSS
Inc, Chicago, IL). All statistical tests were two-sided and a p <
0.05 was considered statistically significant.Available online http://breast-cancer-research.com/content/10/5/R79
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Results
Immunohistochemical HMG-CoAR expression in 
invasive breast cancer
The specificity of the anti HMG-CoAR antibody was confirmed
in a previous study [16]. In the current study, HMG-CoAR
expression was evaluated in 444 cases. On the TMA (n = 54)
missed tumour cores were either lost during immunohisto-
chemistry processing or did not contain invasive cancer.
When present, HMG-CoAR was generally expressed in the
majority of tumour cells (>50%) and, therefore, only the stain-
ing intensity was accounted for in the statistical analyses. One
hundred and eleven (25%) tumours lacked HMG-CoAR
expression (fraction of positive cells <1%), 204 (45.9%) dem-
onstrated weak expression, 117 (26.4%) had moderate
expression and 12 (2.7%) had a strong signal. Figure 1 shows
examples of tumours with different staining intensities, from
negative to strong staining. In some cases, the staining was
accentuated towards the membrane and a few cases dis-
played a coarse, granular cytoplasmic staining. Different sub-
cellular localisations were, however, not accounted for in the
statistical analyses.
Correlation between HMG-CoAR and relevant 
clinicopathological parameters
In order to confirm and validate our previous findings [16],
HMG-CoAR protein expression data were dichotomised into
absent staining versus any staining. As demonstrated in table
1, and in line with previous findings, HMG-CoAR expression
was associated with a smaller tumour size (p = 0.007), low
histological grade (p < 0.001), ER positivity (p = 0.01) and low
proliferation (Ki67; p = 0.02). No association was evident
between HMG-CoAR expression and lymph node status,
patient age or PR status. We used a 10% cut-off to determine
hormone receptor (HR) status; however, comparison of HMG-
CoAR expression with more defined categories of HR positiv-
ity, for example 0 to 10%, 11 to 50%, 51 to 75% and more
than 75%, did not change these associations considerably, as
did neither ER (p = 0.04) or PR (0.88). The correlations shown
in table 1 refer to absent versus present HMG-CoAR expres-
sion, corresponding to the dichotomised variable used for sur-
vival analyses, but similar associations were seen between
HMG-CoAR expression and relevant clinicopathological
parameters when the former was categorised as 0 to 4, as in
the previous study [12] (data not shown).
HMG-CoAR is associated with an improved prognosis
Having demonstrated that HMG-CoAR protein expression
was associated with a less aggressive phenotype, we pro-
ceeded to examine the relationship between HMG-CoAR
expression and breast cancer recurrence. For survival analy-
ses, a dichotomised variable defined as absent staining versus
any staining was used. As illustrated in figure 2a, HMG-CoAR
protein expression was associated with an improved RFS (p =
0.002). Subset analysis revealed that the favourable impact on
outcome associated with HMG-CoAR expression was even
more evident in ER-positive tumours (p < 0.0001), in contrast
to the ER-negative subgroup, where the trend was reversed,
but did not reach statistical signficance (p = 0.24). In the
entire cohort, HMG-CoAR expression was not associated with
an improved BCSS (p = 0.16); however, subset analysis again
revealed an improved BCSS in ER-positive tumours (p = 0.05)
and an inverse, but non-significant, trend for ER-negative
tumours (p = 0.10) (data not shown). These data would sug-
gest that HMG-CoAR expression is associated with a poor
prognosis in ER-negative tumours. Stratification for PR and ER
and/or PR positivity status provided similar results (data not
shown).
We proceeded to perform a Cox regression proportional haz-
ards analysis of RFS and BCSS, which demonstrated esti-
mates of relative risks according to tumour-specific HMG-
CoAR expression in univariate and multivariate analyses (Table
2). Multivariate analyses were adjusted for age at diagnosis,
ER, tumour size, NHG, node status and HER2. Patients with
HMG-CoAR-positive tumours had a significantly improved
RFS compared with patients with HMG-CoAR-negative
tumours independent of adjusted factors (relative risk [RR] =
0.64, 95% confidence interval [CI] 0.43 to 0.94, p = 0.002).
When the analysis was confined to ER-positive patients (n =
375) the results became even more significant (RR = 0.47,
95% CI 0.30 to 0.73, p < 0.001), whereas no association
between HMG-CoAR status and RFS was found in the cohort
of ER-negative tumours (Table 2).
In light of the apparent influence of ER status on the prognos-
tic impact of HMG-CoAR expression, the relationship
between ER and HMG-CoAR was examined in a Cox multivar-
Figure 1
Immunohistochemical images of HMG-CoA reductase staining Immunohistochemical images of HMG-CoA reductase staining. 
Images (×400) representing tumours with (a) negative, (b) weak, (c) 
moderate and (d) strong immunohistochemical staining intensity for 
HMG-CoA reductase.Breast Cancer Research    Vol 10 No 5    Borgquist et al.
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Table 1
Correlation betweeen HMG-CoAR expression and clinicopathological parameters.
HMG-CoAR intensity 0 1 to 3
n (%) 111 (25.0) 333 (75.0) p value
Age (years)
Median 65 64
Range 27 to 89 34 to 96 0.84
≤50 23 (20.7) 51 (15.5)
>50 88 (79.3) 279 (84.5) 0.20
Tumour size (mm)
Median 20 15
Range 1 to 100 1 to 100 <0.001
≤20 mm 57 (51.4) 217 (65.8)
>20 mm 54 (48.6) 113 (34.2) 0.007
NHG
I 11 (9.9) 97 (29.5)
II 45 (40.5) 133 (40.4)
III 55 (49.5) 99 (30.1) <0.001
Node status
Negative 67 (65.7) 179 (61.3)
Positive 35 (34.3) 113 (38.7) 0.43
Unknown 9 41
ER status
Negative 22 (20.0) 36 (10.9)
Positive 88 (80.0) 294 (89.1) 0.01
Unknown 1 3
PR status
Negative 16 (14.8) 45 (13.8)
Positive 92 (85.2) 281 (86.2) 0.79
Unknown 3 7
n (%) 111 (25.0) 333 (75.0) p-value
Endocrine therapy (tamoxifen)
No 50 (55) 147 (59)
Yes 41 (45) 103 (41)
Unknown 20 83 0.53
Chemotherapy
No 81 (89) 240 (95)
Yes 10 (11) 12 (5)
Unknown 20 81 0.04
HER2 IHC
0 77 (73.3) 155 (48.9)
1 13 (12.4) 89 (28.1)
2 6 (5.7) 37 (11.7)
3 9 (8.6) 36 (11.4) <0.001Available online http://breast-cancer-research.com/content/10/5/R79
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iate interaction analysis. This revealed a significant interaction
between ER and HMG-CoAR expression related to both RFS
(p = 0.004) and BCSS (p = 0.01) (table 2). When adjusted
for established prognostic parameters, the interaction
remained significant for RFS (p = 0.01) but not BCSS (p =
0.11). The different impact on survival in strata with different
combinations of ER status and HMG-CoAR expression is fur-
ther illustrated in figure 3, which identified the ER negative/
HMG-CoAR positive group as those with the shortest survival,
both in terms of RFS and BCSS.
Adjusting for adjuvant tamoxifen treatment did not alter the
impact of HMG-CoAR on RFS or BCSS and the interaction
between ER and HMG-CoAR was significant for RFS and
BCSS in both univariate and multivariate analyses (data not
shown).
Correlations between HMG-CoAR and relevant 
clinicopathological parameters in ER-positive and ER-
negative tumours
The apparent influence of HR status on the prognostic impact
of HMG-CoAR led us to further examine the correlations
between HMG-CoAR and established clinicopathological
parameters stratified according to ER status (Table 3). This
revealed an apparent discrepancy between the two groups,
with a strongly positive association between HMG-CoAR pos-
itivity and nodal status in ER-negative patients (n = 58) (p <
0.001). Furthermore, no correlations between tumour size,
NHG or proliferation and HMG-CoAR expression were evi-
dent in the ER-negative group. In contrast, in the ER-positive
subgroup the association with favourable parameters such as
small tumour size (p = 0.03), low NHG (p < 0.001) and Ki-67
negativity (p = 0.05) was retained. In addition, no association
was seen between HMG-CoAR and nodal status in the ER-
positive group.
Discussion
The present study confirms previous data identifying a correla-
tion between tumour-specific HMG-CoAR expression and
prognostic favourable clinicopathological parameters in breast
cancer. In addition, the analysis of tumour specimens from a
consecutive cohort of 498 breast cancer patients with long-
term follow-up, revealed that HMG-CoAR expression is an
independent predictor of RFS. Nevertheless, these data indi-
cate that this beneficial influence is not extended to ER-nega-
tive tumours in which the impact on survival may in fact be the
reverse. This assumption is supported by a significant interac-
tion between ER status and HMG-CoAR expression in terms
of both RFS and BCSS. The significant impact on prognosis
was not only retained, but augmented when adjustment for
adjuvant tamoxifen treatment was included in the multivariate
analysis. Although this indicates that the prognostic value of
HMG-CoAR is independent of tamoxifen treatment, we prefer
not to draw any further conclusions, because this cohort, while
providing robust prognostic data, was less well suited for eval-
uating treatment predictive effects. Such analyses should ide-
ally be performed on tumour specimens from randomised
trials. In this cohort, patients treated with tamoxifen had a sig-
nificantly poorer survival compared with untreated subjects,
reflecting the fact that they were diagnosed during an era
where tamoxifen was primarily given to patients with more
advanced disease. Also, as shown in table 3, a fraction of the
ER-negative patients received tamoxifen, but this did not alter
the effect of HMG-CoAR on survival in this subgroup.
The number of patients that had received adjuvant chemother-
apy was too small (n = 23) to allow for evaluation of how this
could have affected the results in the ER-negative group.
Despite a plethora of literature on the anti-neoplastic proper-
ties of statins, epidemiological data about their cancer pre-
venting effect in general and breast cancer in particular are not
unknown 6 16
HER2 IHC
0 to 2 96 (91) 284 (89)
3 9 (9) 36 (11) 0.44
Unknown 6 16
Ki67
0 to 10% 29 (27.6) 122 (39.5)
11 to 25% 35 (33.3) 107 (34.6)
>25% 39 (41.0) 80 (25.9) 0.02
Unknown 8 24
ER = oestrogen receptor; HER2 = human epidermal growth factor receptor 2; IHC = immunohistochemistry; NHG = Nottingham histological grade; PR = 
progesterone receptor.
10% cut-off used for determination of hormone receptor status. Mann-Whitney test for comparison of medians and chi squared test for X × 2 tables. The categories 
marked as not done and unknown were not included in the analysis.
Table 1 (Continued)
Correlation betweeen HMG-CoAR expression and clinicopathological parameters.Breast Cancer Research    Vol 10 No 5    Borgquist et al.
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Figure 2
Recurrence-free survival according to HMG-CoA reductase expression Recurrence-free survival according to HMG-CoA reductase expression. Kaplan-Meier estimates of recurrence-free survival according to HMG-
CoA reductase expression, defined as negative (0) or positive (1 to 3), in all (a) patients, and in patients with (b) oestrogen receptor (ER) positive 
tumours and (c) ER-negative tumours.Available online http://breast-cancer-research.com/content/10/5/R79
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conclusive [9,17-20]. Although breast cancer is a truly heter-
ogeneous disease, consisting of several molecular subgroups
that still need to be further refined in order to optimise treat-
ment protocols, it is reasonable to assume that the mevalonate
pathway plays a key role in certain subgroups. As shown in
table 3, our data clearly show diverging associations to clinico-
pathological parameters in ER-positive and ER-negative
tumours, with a strong association between HMG-CoAR
expression and lymph node positivity in ER-negative tumours.
Previous studies have demonstrated that ER-negative cell
lines are more sensitive to growth inhibition by statins than
their ER-positive counterparts [10]. We are not aware of any
studies related to statin response in ER-negative versus ER-
positive tumours in vivo, but ongoing prospective trials will
hopefully shed more light on this issue. ER-status alone, how-
ever, does not divide tumours into clinically relevant subgroups
and additional surrogate markers are needed to select patients
that would benefit from statin treatment. It is evident that the
enzyme that is targeted by statins, HMG-CoAR, is expressed
in breast cancer and that it, in the overall setting, predicts a
good prognosis, but probably not in ER-negative tumours.
These data suggest that an elevated HMG-CoAR expression
may be a relevant surrogate marker of response to statin treat-
ment, both in the adjuvant and chemopreventive setting, in ER-
negative tumours.
Given the small number of ER-negative tumours present in this
study and the risk of random associations with multiple sub-
group analyses, this assumption must, however, be confirmed
in prospective trials and in larger numbers of ER-negative
tumours. Moreover, further studies are warranted to examine
the role of HMG-CoAR as a predictor of statin treatment
response in triple negative tumours (ER-negative, PR-negative
and HER2-negative). Although HER2 amplification status was
not available for the tumours in the present study, no firm con-
clusions can be drawn. Interestingly, in ER-negative and PR-
negative tumours expressing HMG-CoAR (n = 40), a nega-
Table 2
Cox univariate and multivariate analysis of recurrence-free and breast cancer-specific survival according to HMGCoA-reductase 
expression in all, oestrogen receptor (ER) positive and ER-negative patients.
Recurrence-free survival Breast cancer-specific survival
RR (95%CI) p value RR (95%CI) p value
All patients Univariate Univariate
HMG-CoAR negative 1.00 1.00
HMG-CoAR positive 0.57 (0.40 to 0.82) 0.002 0.64 (0.91 to 1.03) 0.07
Multivariate Multivariate
HMG-CoAR negative 1.00 1.00
HMG-CoAR positive 0.60 (0.40 to 0.92) 0.02 0.66 (0.39 to 1.11) 0.12
ER positive Univariate Univariate
HMG-CoAR negative 1.00 1.00
HMG-CoAR positive 0.46 (0.31 to 0.69) <0.001 0.59 (0.34 to 1.00) 0.02
ER negative
HMG-CoAR negative 1.00 1.00
HMG-CoAR positive 1.68 (0.70 to 4.03) 0.25 2.47 (0.81 to 7.54) 0.11
Term of interaction* 0.004* 0.01*
ER positive Multivariate Multivariate
HMG-CoAR negative 1.00 1.00
HMG-CoAR positive 0.47 (0.30 to 0.73) 0.001 0.67 (0.38 to 1.17) 0.16
ER negative
HMG-CoAR negative 1.00 1.00
HMG-CoAR positive 1.45(0.35 to 5.97) 0.61 2.00 (0.37 to 10.93) 0.42
Term of interaction* 0.01* 0.11*
Multivariate analysis adjusted for Nottingham histological grade (I–II/III), age (continuous), nodal status(0/1), and tumour size (continuous). ER status (positive/negative, 
10% cut-off), and human epidermal growth receptor 2 (HER2) immunohistochemistry 0 to 2 vs 3. * =  p value for term of interaction including ER (0/1), HMG-CoAR (0/
1) and an interaction variable.Breast Cancer Research    Vol 10 No 5    Borgquist et al.
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tive/low expression of HER2 (immunohistochemistry 0 to 2)
was associated with a significantly shorter RFS (RR = 3.92,
95%CI 1.25 to 12.36, p = 0.02), but not BCSS (data not
shown), compared with tumours with high expression of HER2
(immunohistochemistry 3). In contrast, among ER-negative/
PR-negative/HMG-CoAR-negative tumours HER2 status had
no prognostic impact on either RFS or BCSS (data not
shown).
Data on statin use was not available for the patients in this
cohort, but it can be assumed that the number of users was
negligible during that period of time. In the Malmö Diet and
Cancer Study, which was initiated in 1991, the number of sta-
tin users at baseline was too small, only 228 of 17,035 female
participants, to allow for analyses of tumour-specific HMG-
CoAR expression in relation to previous statin use [16]. Such
studies would, however, be of interest, especially with regard
to the reported lower incidence of ER-negative tumours
among statin-users [10]. The focus of the current study was to
Figure 3
Recurrence-free and breast cancer-specific survival according to combinations of oestrogen receptor (ER) status and HMG-CoA reductase  expression Recurrence-free and breast cancer-specific survival according to combinations of oestrogen receptor (ER) status and HMG-CoA reductase 
expression. Kaplan-Meier estimates of (a) recurrence-free and (b) breast cancer-specific survival according to combinations of ER-status (negative/
positive) and HMG-CoA reductase expression (negative [0]/positive [1 to 3]).Available online http://breast-cancer-research.com/content/10/5/R79
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Table 3
Correlation betweeen HMGCoAR expression and clinicopathological parameters in oestrogen receptor (ER) positive and ER-
negative tumours.
ER-positive ER-negative
HMG-CoAR intensity 0 1–3 0 1–3
n (%) 88 (23) 294 (77) p value 22 (38) 36 (62) p value
Age (years)
Median 66 65 57 59
Range 28–89 35–96 0.43 27–81 34–90 0.38
≤50 15 (17) 45 (15) 7 (32) 8 (27)
>50 73 (83) 249 (85) 0.69 15 (68) 28 (73) 0.42
Tumour size
Median 20 15 22 17
Range 1 to 100 1 to 100 <0.001 12 to 55 1 to 100 0.10
≥20 mm 48 (55) 147 (60) 9 (41) 19 (53)
>20 mm 40 (45) 97 (40) 0.03 13 (59) 17 (47) 0.38
NHG
I 11 (13) 95 (32) 0 1 (3)
II 40 (45) 126 (43) 5 (23) 9 (25)
III 37 (42) 72 (25) <0.001 17 (77) 26 (72) 0.56
Node status
Negative 48 (59) 167 (64) 19 (90) 11 (36)
Positive 33 (41) 95 (36) 0.47 2 (10) 19 (63) <0.001
Unknown 7 32 1 6
Tamoxifen
No 41 (55) 133 (60) 8 (50) 12 (44)
Yes 33 (45) 87 (40) 0.45 8 (50) 15 (56) 0.73
Unknown 14 74 6 6
Chemotherapy
No 67 (91) 214 (96) 14 (88) 23 (85)
Yes 7 (9) 8 (4) 0.05 2 (12) 4 (15) 0.84
Unknown 14 72 6 6
HER2 IHC
0 59 (71) 144 (51) 17 (81) 12 (34)
1 13 (16) 85 (30) 0 5 (14)
2 6 (7) 35 (12) 0 1 (3)
3 5 (6) 19 (7) 0.02 4 (19) 17 (49) 0.007
Unknown 5 11 1 1
HER2 IHC
0 to 2 78 (94) 264 (93) 17 (80) 18 (51)Breast Cancer Research    Vol 10 No 5    Borgquist et al.
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investigate the impact of tumour-specific HMG-CoA reduct-
ase expression on disease outcome in primary breast cancer
with possible implications to its relevance in a tumour biologi-
cal, not epidemiological, context. However, given the
association between tumour-specific HMG-CoAR expression
and ER-positive tumours, which we have now observed in two
large breast cancer cohorts, it would be interesting to see
whether this association is altered in ER-positive tumours in
previous statin users. It can not readily be hypothesised that
the use of statins, which inhibit HMG-CoAR expression, would
promote the incidence of a tumour phenotype linked to a
higher expression of the enzyme. It would also be of interest to
examine whether HMG-CoAR expression is affected in ER-
negative tumours that still occur among statin users, that is, if
the proportion of HMG-CoAR expressing tumours is reduced.
Conclusion
The target enzyme for cholesterol-lowering statins, HMG-
CoAR, is associated with improved prognosis among ER-pos-
itive breast cancer patients, whereas ER-negative patients
seem to have a better outcome when HMG-CoAR is absent.
Future randomised trials are warranted to clarify the potential
beneficial effects of statins in the adjuvant and metastatic
setting.
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